- Home
- AVTX vs GLO Comparison
AVTX vs GLO Comparison
Compare AVTX & GLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVTX | GLO |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 243.8M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVTX | GLO |
|---|---|---|
| Price | $17.11 | $5.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $32.29 | N/A |
| AVG Volume (30 Days) | ★ 302.8K | 170.5K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.38% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $192,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.39 | $4.08 |
| 52 Week High | $20.72 | $5.18 |
Technical Indicators
Market Signals| Indicator | AVTX | GLO |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 63.36 |
| Support Level | $15.49 | $5.65 |
| Resistance Level | $18.54 | $5.71 |
| Average True Range (ATR) | 1.17 | 0.05 |
| MACD | -0.28 | 0.02 |
| Stochastic Oscillator | 44.93 | 90.32 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.